Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in COPD with a History of Exacerbations
NCT02546700Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of lebrikizumab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Started Sep 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02546700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546700.